LILRB1 and neoplasm: Disrupting either MHC-I or LILRB1 can facilitate phagocytosis, suggesting that the MHC-I/LILRB1 axis plays a vital role in inhibiting macrophage phagocytosis, which shows potential to be a possible marker for therapeutic response to CD47-targeted agents and target of anti-tumor therapy [37].